You are here: Home » 2021 » September » Archives for 14th

Blackstone Completes Previously Announced Acquisition of Sphera, Leading Provider of ESG Software, Data, and Consulting Services

NEW YORK and CHICAGO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Sphera today announced that private equity funds managed by Blackstone (NYSE: BX, "Blackstone") have completed their previously announced acquisition of Sphera, a leading provider of environmental, social and governance (ESG) software, data and consulting services, from Genstar Capital. The transaction, which values the company at $1.4 billion, continues Blackstone's thematic investment focus on the ESG sector and provides Sphera with capital to help accelerate its growth and product offerings.

Spanning over 80 countries with more than 3,000 customers, Sphera combines its software as a service solution with consulting services, underpinned by proprietary data, to support businesses globally to manage and mitigate ESG risk. This support is delivered through its three product lines: Environment, Health, Safety & Sustainability (EHS&S); Operational Risk Management; and Product Stewardship.

As part of Sphera's strategic growth efforts, the company is also announcing the appointment of Kimberly Kolb as chief human resources officer (CHRO). As CHRO, Kolb will be responsible for developing and supporting Sphera's global workforce as the organization continues to grow its footprint worldwide. She brings over 30 years of human resources, consulting and marketing experience from technology, professional service and financial services firms to the position, and held senior leadership roles at Whittman–Hart, CME Group and XR Trading.

Paul Marushka, CEO and president at Sphera, said, "As we enter this new stage, we are excited to be able to partner with Blackstone. Our achievements to date are a result of the dedication, hard work and effort of the team at Sphera. I am proud to collaborate with such a dedicated team as we take Sphera, with Blackstone's investment and support, to the next level. This partnership with and capital injection by Blackstone will facilitate the next evolution of innovation, cementing our position as leaders and allowing us to push ahead with our vision for ESG software integration with extensive data and world–class consultancy services."

Eli Nagler, a senior managing director at Blackstone, said: "We are excited to partner with Paul Marushka and his team to build on Sphera's strong momentum as a trusted leader in the ESG solutions space. We look forward to supporting the company in the next phase of its growth journey as they continue to expand their product offerings and innovate to best serve their global customer base."

Note to editors

About Sphera
Sphera creates a safer, more sustainable and productive world. We are a leading global provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services with a focus on Environment, Health, Safety & Sustainability (EHS&S), Operational Risk Management and Product Stewardship. Learn more about Sphera at www.sphera.com. Follow Sphera on LinkedIn.

About Blackstone
Blackstone is one of the world's leading investment firms. We seek to create positive economic impact and long–term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $684 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, life sciences, growth equity, opportunistic, non–investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.

Contact:

Sphera Solutions, Sphera@AspectusGroup.com


GLOBENEWSWIRE (Distribution ID 8325748)

Madison Realty Capital Originates $450 Million Construction Loan for 1,098-unit Mixed Use Development in Downtown Brooklyn

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) — Madison Realty Capital, a vertically integrated real estate private equity firm focused on debt and equity investment strategies, today announced it has provided a $450 million loan to The Rabsky Group, one of the largest residential and commercial developers in Brooklyn and Queens, to complete development of a 1,098–unit, 35–story multifamily and retail mixed–use property at 625–635 Fulton Street at the intersection of Flatbush Avenue in Downtown Brooklyn, New York.

Josh Zegen, Managing Principal and Co–Founder of Madison Realty Capital, said, "This transaction represents Madison Realty Capital's ability to deliver speed, certainty, and execution to top–tier borrowers in highly attractive submarkets. Accordingly, we are pleased to provide The Rabsky Group, a highly sophisticated and experienced developer with significant holdings throughout the New York metropolitan area, with a large and flexible financing solution. Downtown Brooklyn is an ever–expanding neighborhood and new multifamily housing options, particularly of this caliber, will be quickly absorbed. We are glad to support a property under development that will offer significant affordable housing options and look forward to expanding our relationship with The Rabsky Group for additional projects that positively impact New York City."

Brooklyn is New York City's most populous borough and is home to one of the most diverse economies in the country. Proximity to major employment hubs and education centers have made Downtown Brooklyn one of New York's fastest growing residential markets. Moreover, Downtown Brooklyn has also become a technology and innovation hub and is home to 25 percent of New York City–based tech firms. The property is located within the Brooklyn Tech Triangle, an area comprised of Downtown Brooklyn, DUMBO, and the Brooklyn Navy Yard that has emerged as New York City's largest cluster of tech activity outside of Manhattan and is within two blocks of ten different subway lines.

Designed with two interconnected residential towers atop a five–story podium, the property will offer 590,096 rentable residential square feet across 342 studios, 492 one–bedroom and 264 two–bedroom units and 30% of the units will be affordable through the Affordable New York program. A portion of the affordable units will be part of the Inclusionary Housing Program for lower income tenants. Residents will enjoy top–of–the–line amenities including a fitness facility, spa, recreation areas, in–unit washers and dryers, lounges, and a rooftop outdoor pool with views of Manhattan and Brooklyn. In addition to best–in–class residential units the property will have 25,988 rentable square feet of retail space along Fulton Street, 250 parking spaces and 150 storage units.

The Rabsky Group is led by Simon Dushinsky, Yadler Rabinowitz, and Joel Gluck, who also contributed significant cash equity for the construction.

Henry Bodek of Galaxy Capital served as broker for the transaction.

About Madison Realty Capital

Madison Realty Capital is a vertically integrated real estate private equity firm that manages approximately $6 billion in total assets on behalf of an institutional global investor base. Since 2004, Madison Realty Capital has completed more than $15 billion in transactions in the U.S. providing reputable borrowers with flexible and highly customized financing solutions, strong underwriting capabilities, and certainty of execution. Headquartered in New York City, with offices in Los Angeles and Miami, the firm has over 60 employees across all real estate investment, development, and property management disciplines. Madison Realty Capital has been frequently named to the Commercial Observer's prestigious "Power 100" list of New York City real estate players and is consistently cited as a top construction lender, among other industry recognitions. To learn more, follow us on LinkedIn and visit www.madisonrealtycapital.com.


GLOBENEWSWIRE (Distribution ID 8325195)

Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director

CAMBRIDGE, United Kingdom, Sept. 14, 2021 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, today announced the appointments of Andre Nel, Dalila Rahmani, Laura D'Angelo and Omar Elbakshish to the company's management team, expanding its global leadership to help scale the growing business.

"We are thrilled to welcome Andre, Dalila, Laura and Omar to the expanding leadership team here at Dante," said Andrea Riposati, CEO of Dante Labs. "As we work to deliver a more human approach to healthcare, it is our shared vision of the future and growing importance genomics is playing in healthcare that will help to meet the unmet needs of our customers from whole genome sequencing to drug discovery and development to COVID testing."

These leaders will join Dante's finance team to help scale the business as we work to deliver a global brand of tests and services resulting in better outcomes for people around the world.

Leading the team, Andre Nel joins Dante Labs as Chief Financial Officer. Andre brings more than 20 years of experience providing high–value strategic and operational financial support for global multibillion–dollar organizations such as Pfizer and Illumina. Most recently, Andre was the Vice President of Finance at Illumina (NASDAQ: ILMN) in San Diego.

Dalila joins Dante Labs as the Chief Accounting Officer. Dalila previously worked with Andre at Illumina as the head of Controllership and Shared Services for the EMEA region. Dalila has most recently led the Illumina Commercial Finance team, specializing in financial forecasting, budgeting, business partnering and management. Prior to joining Illumina she started her career as an auditor with Ernst & Young. Dalila has a demonstrated history working in the biotechnology industry and a master's degree focused on Accounting and Finance. Her work in the industry will benefit us greatly in our more personalized approach to medicine and healthcare.

Laura D'Angelo joins Dante Labs as Vice President of Investor Relations. Most recently, Laura was the Head of Investor Relations at Invitae (NYSE: NVTA), specializing in external communication targeting analysts, investors and financial media as well as clinician and patient customers. With a career rooted in communications, Laura brings a unique perspective to Dante's finance team as we turn sequencing data into life–saving answers for the people we serve.

Omar Elbakshish joins Dante Labs as Senior Director of Business Finance. Skilled in financial modeling, forecasting and business partnering, Omar also joins Dante from Illumina. With a demonstrated history working in finance roles in the biotechnology industry throughout his career, Omar will help Dante to deploy genomic applications that have real impact on people's lives.

"I'm so pleased to be leading this passionate and talented finance team here at Dante Labs to help accelerate genomics on a global scale to improve healthcare outcomes," said Andre Nel, Chief Financial Officer of Dante Labs. "Having worked previously with Dalila and Omar and now collaborating with Laura, I'm confident we have the right team of professionals to achieve our mission and demonstrate how essential genomics is to a holistic and human approach to healthcare around the world."

About Dante Labs
Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Headquartered in Cambridge, United Kingdom, with a research laboratory in Wolverhampton, Dante Labs supported the UK Government's urgent requirement to scale–up a high–capacity, highly automated testing solution for Covid–19, including infected patients as well as those with antibodies. Dante Labs was able to deliver by leveraging existing technology that had been developed for whole genome sequencing.

Contact
Giorgio Lodi
media@dantelabs.com
+39 0862 191 0671
www.dantelabs.com


GLOBENEWSWIRE (Distribution ID 8325589)

Tech Companies Datamaran and Intelex Team Up to Provide a Full-Suite ESG Software Solution

Toronto, Canada, Sept. 14, 2021 (GLOBE NEWSWIRE) — Intelex Technologies, ULC, a leading global provider of cloud–based Environmental, Health, Safety and Quality (EHSQ) management software, today announced it has entered an exclusive reseller partnership with Datamaran , the only automated solution available to achieve a data–driven business process for external risk and materiality analysis. Working together, Datamaran and Intelex are helping customers accelerate their strategic and operational goals with a single source, fully automated and data–driven process.

Justin McElhattan, President and CEO of Intelex said, "We are very excited to partner with Datamaran to provide our customers with Datamaran's industry–leading risk monitoring and materiality intelligence. Alongside Datamaran, we are able to offer our customers a superb experience that allows them to accelerate their ESG transformation by applying best–in–class data science and analytics."

With this exclusive reseller partnership, Intelex customers will use Datamaran to identify, monitor and gain insights into emerging business and social issues with a dynamic risk and materiality process. The partnership provides organizations with unique risk monitoring and materiality capabilities, including Datamaran for Executives, a comprehensive solution to ensure that the most complete set of material risks are accurately captured for risk management, transparently communicated in annual disclosures and consistently reported up to the board of directors.

Mirroring Intelex's own approach to providing scalable solutions that match customer ESG requirements, the Datamaran partnership offers customers the flexibility they need to achieve their strategic objectives. With Intelex and Datamaran together, organizations can seamlessly manage and monitor their ESG initiatives, reporting and strategy.

Companies worldwide use Datamaran's evidence–based approach to inform their materiality, risk management, board oversight and reporting processes. This approach allows them to stay ahead of the curve, in front of the competition and at the top of their game. For an actual use case, you don't have to look farther than Intelex parent company Fortive.

Pete Underwood, SVP and General Counsel of Fortive explains: "Datamaran continually anticipates and meets our needs, as our ESG and risk management processes evolve and mature. The platform enables a clear view of business–critical issues across the ever–changing landscape."

With Datamaran and Intelex, senior management communicate timely and relevant information to the board of directors, move materiality from an operational exercise to a strategic process and monitor emerging trends. Using AI, Datamaran's patented technology identifies and monitors over 400 external risk factors""including ESG, innovation and technology and geopolitical issues""on an ongoing basis by scanning the regulatory, media and corporate disclosure environments. It is the only software analytics platform available to improve risk management, annual reporting and board oversight of external risks and opportunities.

"For the past seven years, blue–chip companies have chosen Datamaran to seriously improve the way in which they go about ESG," said Marjella Lecourt–Alma, CEO and co–founder of Datamaran. "With Intelex, we're excited to reach an even larger group of companies. As a software provider with deep expertise in EHS, Intelex understands that ESG is now dominating the corporate market. Our full–suite ESG software solution enables companies to quickly move sustainability from project to process."

###

About Datamaran: Datamaran is the only software analytics platform in the world that identifies and monitors external risks, including ESG. Trusted by blue–chip companies and top tier partners, it brings a data–driven business process for external risk and materiality analysis. In house""at any time. Datamaran's patented technology offers real–time analytics on strategic, regulatory and reputational risks, specific to your business and value chain.

About Intelex Technologies, ULC: Intelex is a global leader in environmental, health, safety and quality (EHSQ) management software. Since 1992, Intelex employees across the globe have been committed to innovating and enabling organizations to send their employees home safely every day, leaving behind a more sustainable world to the generations that follow, and manage quality so that only the safest and highest quality products make it to market.

Intelex's scalable, web–based platform and applications have helped clients across all industries improve business performance, mitigate organization–wide risk, and ensure sustained compliance with internationally accepted standards (e.g. ISO 9001, ISO 14001, ISO 45001) and OSHAS 18001) and regulatory requirements. Almost 1,400 customers in 195 countries trust Intelex to power their EHSQ initiatives.

Headquartered in Toronto with regional offices and employees around the world, Intelex became an Industrial Scientific company in 2019. In 2020, Intelex acquired ehsAI, provider of a SaaS–based next–wave compliance automation solution that leverages artificial intelligence and machine learning algorithms. For more information about Intelex, visit www.intelex.com.


GLOBENEWSWIRE (Distribution ID 8324859)

Anaqua Delivers Enhanced IP Management to Bausch Health

BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) — Anaqua, the leading innovation and intellectual property management technology provider, today announced that Bausch Health Companies Inc. has selected Anaqua's AQX platform to deliver enhanced IP management across the health care products company's global operations.

Bausch Health will be using Anaqua's AQX as their primary IP management system – both for patent and trademark management – replacing their previous IP services provider. Bausch Health will take advantage of Anaqua's broad range of IP offerings including AcclaimIP for patent analytics, Anaqua Services for patent annuities and trademark renewals, as well as AQX modules for IP contract and financial management.

Commented Bob Romeo, CEO of Anaqua: "Bausch Health is an innovative health care company delivering on its commitment to help people around the world. We are proud to be working with them and to better serve their valuable IP assets through Anaqua's enhanced innovation and IP management solutions."

About Anaqua
Anaqua, Inc. is a premium provider of integrated intellectual property (IP) management technology solutions and services. Anaqua's AQX platform combines best practice workflows with big data analytics and tech–enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision–making, and streamline IP operations. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua's solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs. The company's global operations are headquartered in Boston, with offices across the U.S., Europe, and Asia. For additional information, please visit anaqua.com, or on LinkedIn.

Company Contact:
Amanda Hollis
Associate Director, Communications
Anaqua
617–375–2626
ahollis@Anaqua.com


GLOBENEWSWIRE (Distribution ID 8325083)

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio System for Obstructive Sleep Apnea and Complete Concentric Collapse

Mont–Saint–Guibert (Belgium), September 14, 2021, 8:00 am CET / 2:00 am ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the U.S. Food and Drug Administration (FDA) has granted the Genio bilateral hypoglossal nerve stimulation system Breakthrough Device Designation for the treatment of adult patients with moderate to severe OSA and Complete Concentric Collapse (CCC) of the soft palate.

The FDA's Breakthrough Designation Program was created to help patients and healthcare providers receive faster access to innovative technologies that hold the potential to provide more effective treatment of irreversibly debilitating diseases or conditions. According to the FDA, OSA is an irreversibly debilitating human disease for patients with sleep apnea. Under the Program, the FDA will provide the Genio system with priority review and interaction with FDA's experts throughout the premarket review phase until the product is commercialized in the US.

"We are pleased to have received Breakthrough Device Designation for our proprietary Genio system for OSA patients with CCC, recognizing that Obstructive Sleep Apnea is an irreversibly debilitating condition." said Olivier Taelman, CEO of Nyxoah. "This Breakthrough Designation accelerates our market authorization process in the US and expands our total addressable market to include CCC patients currently contraindicated for hypoglossal nerve stimulation."

The Breakthrough Designation is supported by data from the Company's BETTER SLEEP trial, aimed at addressing the long–term safety and performance of the Genio system in adult OSA patients with and without CCC.

About BETTER SLEEP Trial
BilatEral Hypoglossal Nerve StimulaTion for TreatmEnt of ObstRuctive SLEEP Apnoea, or BETTER SLEEP, is a multicenter, prospective, open–label, two–group clinical trial, designed to assess the safety and performance of the Genio system for the treatment of OSA in adult patients with and without CCC. Top–line BETTER SLEEP results showed primary safety and performance endpoints were met, with statistically significant mean reduction in the AHI score in full patient population including CCC patients. Nyxoah will submit full BETTER SLEEP study data to a medical journal for publication and announce results following further analyses.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah is seeking for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
corporate@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment


GLOBENEWSWIRE (Distribution ID 1000546914)